Aflibercept – July 2026

  • Solution for intravitreal injection 3.6 mg in 90 microlitres (40 mg per mL) pre-filled syringe
  • Solution for intravitreal injection 4 mg in 100 microlitres (40 mg per mL)

  • Brand names:
    • Eydenzelt®
  • Pharmaceutical Company:
    • CELLTRION HEALTHCARE AUSTRALIA PTY LTD
  • Condition/Indication: Branch retinal vein occlusion with macular oedema; Central retinal vein occlusion with macular oedema; Diabetic macular oedema; Subfoveal choroidal neovascularisation due to age-related macular degeneration
  • Meeting Date: July 2026

Last updated
20 November 2026